STM Journals Peer-reviewed research from Consortium e-Learning Network

Research and Reviews: A Journal of Pharmacology

Treatment and management of Hypertension using Combinatorial therapy: A recent Approach

  1. Pratik Kumar Vishwakarma
  2. Meera Kumari
  3. Amresh Gupta

Abstract

One of the most frequent and widespread illnesses is hypertension. Nowadays, several medications are used to treat hypertension but are implicated in having some severe side effects. So, to overcome these side effects, there is the usage of a combination of drugs based on lesser side effects and an increase in efficacy or therapeutic goals. Although the first pharmacological therapy impacts long-term results, lowering blood pressure is the most critical factor in reducing CV risk. According to available statistics, to fulfill current BP goals, at least 75% of patients will require a mix of treatments. Clinical practice is increasingly focusing on the practical aspects of achieving and maintaining target blood pressure regularly. To reach treatment goals, the majority of hypertension patients will need a combo of antihypertensive drugs; current recommendations suggest beginning systolic blood pressure >20 mmHg and diastolic blood pressure >10 mmHg over the objectives, as well as those with a high stroke disease, should receive medical care with two drugs. In this review article, we analyze the recent data that is available to treat hypertension in the combination form of drugs

References (29)

  1. Oparil S, Acelajado MC, Bakris GL, Berlowitz DR, Cifkova R, Dominiczak AF, Grassi G, Jordon J, Poulter NR, Rodgers A, Whelton PK. Hypertension. Nature Reviews Disease Primers. 2018; 4: 18014. doi:10.1038/NRDP.2018.14.
  2. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ. Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991 . Hypertension. (Dallas, Tex. 1979). 1995; 26(1): 60–69p. doi:10.1161/01.HYP.26.1.60.
  3. Sanchez RA, Ayala M, Baglivo H, Velazquez C, Burlando G, Kohlmann O, Jimenez J, Jaramillo PL, Brandao A, Valdes G, Alcocer L, Bendersky M, Ramirez AJ, Zanchetti A; Latin America Expert Group. Latin American guidelines on hypertension . J Hypertens. 2009; 27(5): 905–922p. doi:10.1097/HJH.0b013e32832aa6d2.
  4. Oliva RV, Bakris GL. Management of hypertension in the elderly population. J Gerontol A Biol Sci Med Sci. 2012; 67(12): 1343–1351p. doi:10.1093/GERONA/GLS148.
  5. Stamler J. Blood pressure and high blood pressure. Aspects of risk . Hypertens (Dallas, Tex. 1979). 1991; 18(3 Suppl): I-95-I–107. doi:10.1161/01.HYP.18.3_SUPPL.I95.
  6. Pimenta E, Oparil S. Fixed combinations in the management of hypertension: Patient perspectives and rationale for development and utility of the olmesartan-amlodipine combination . Vascular Health Risk Management. 2008; 4(3): 653–664p. doi:10.2147/VHRM.S2586.
  7. De Lima DP. Synthesis of angiotensin -converting enzyme (ACE) inhibitors: An important class of antihyper tensive drugs . Scielo Brazil . 1999; 22(3): 375–381p. doi:10.1590/S0100 - 40421999000300016.
  8. Abeywardena MY, Jablonskis LT, Head RJ. Age- and hypertension-induced changes in abnormal contractions in rat aorta . J Cardiovasc Pharmacol. 2002; 40(6): 930–937p. doi:10.1097/00005344-200212000-00015.
  9. Üniversitesi I, Fakültesi FE, Bölümü B, Malatya, Selamoğlu Z, Yürekli M. The Effects of Enalapril Maleate and Cold Stress on Some Blood Parameters. Dicle Medical Journal. 2005; 1: 6–12p.
  10. Cushman DW, Cheung HS, Sabo EF, Ondetti A. Design of Potent Competitive Inhibitors of Angiotensin-Converting Enzyme. Carboxyalkanoyl and Mercaptoalkanoyl Amino Acids . Biochemistry. 1977; 16(25): 5484–5491p. doi:10.1021/BI00644A014/SUPPL_FILE/BI00644A014_SI_001.PDF.
  11. Byun HG, Kim SK. Structure and activity of angiotensin I converting enzyme inhibitory peptides derived from alaskan pollack skin . J Biochem Mol Biol. 2002; 35(2): 239–243p. doi:10.5483/BMBREP.2002.35.2.239.
  12. Harris BS, Bishop KC, Kemeny HR, Walker JS, Rhee E, Kuller JA. Risk factors for birth defects. Obstet Gynecol Surv. 2017; 72(2): 123–135p. doi:10.1097/OGX.0000000000000405.
  13. Hayek T, Attias J, Coleman R, Brodsky S, Smith J, Bres low JL, Keider S . The angiotensin - converting enzyme inhibitor, fosinopril, and the angiotensin II receptor antagonist, losartan, inhibit LDL oxidation and attenuate atherosclerosis independent of lowering bl ood pressure in apolipoprotein E deficient mice . Cardiovasc Res. 1999; 44(3): 579–587p. doi:10.1016/S0008 - 6363(99)00239-4/2/44-3-579-FIG6.GIF.
  14. Arihara K, Nakashima Y, Mukai T, Ishikawa S, Itoh M. Peptide inhibitors for angiotensin I - converting enzyme from enzymatic hydrolysates of porcine skeletal muscle proteins . Meat Sci. 2001; 57(3): 319–324p. doi:10.1016/S0309-1740(00)00108-X.
  15. Odović J, Stojimirović B, Aleksić M, Milojković-Opsenica D, Tešiś Z. Reversed-phase thin-layer chromatography of some angiotensin converting enzyme (ACE) inhibitors and their active metabolites. J Serbian Chem Soc. 2006; 71(6): 621–628p. doi:10.2298/JSC0606621O.
  16. Volpe M, Gallo G, Tocci G. Is early and fast blood pressure control important in hypertension management? Int J Cardiol. 2018; 254: 328–332p. doi:10.1016/J.IJCARD.2017.12.026.
  17. Burnier M. Antihypertensive Combination Treatment: State of the Art . Curr Hypertens Rep. 2015; 17(7): 51p. doi:10.1007/S11906-015-0562-0. Research & Reviews: A Journal of Pharmacology Volume 12, Issue 3 ISSN: 2230-9861 (Online), ISSN: 2349-1299 (Print) © STM Journals 2022. All Rights Reserved 7
  18. Wald DS, Law M, Morris JK, Bestwick JP, Wald NJ. Combination therapy versus monotherapy in reducing blood pressure: meta-analysis on 11,000 participants from 42 trials. Am J Med. 2009; 122(3): 290–300p. doi:10.1016/J.AMJMED.2008.09.038.
  19. Rubio-Guerra AF, Castro-Serna D, Elizalde Barrera CI, Ramos-Brizuela LM. Current concepts in combination therapy for the treatment of hypertension: Combined calcium channel blockers and RAAS inhibitors. Integr Blood Press Control. 2009; 2: 55–62p. doi:10.2147/IBPC.S6232.
  20. Chobanian AV. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure . Hypertension. 2003; 42(6): 1206–1252p. doi:10.1161/01.HYP.0000107251.49515.C2.
  21. Bakris GL. Combined therapy with a calcium channel blocker and an angiotensin II type 1 receptor blocker. J Clin Hypertens (Greenwich). 2008; 10(Suppl 1): 27–32p. doi:10.1111/J.1524- 6175.2007.08029.X.
  22. Poldermans D, Glazes R, Kargiannis S, Wernsing M, Kaczor J, Chiang YT, Yen J, Gamboa R, Fomina I . Tolerability and blood pressure -lowering efficacy of the combination of amlodipine plus valsartan compared with lisinopril plus hydrochlorothiazide in adult patients with stage 2 hypertension. Clin Ther. 2007; 29(2): 279–289p. doi:10.1016/j.clinthera.2007.02.003.
  23. Chrysant SG, Fagan T, Glazer R, Kriegman A. Effects of benazepril and hydrochlorothiazide, given alone and in low - and high -dose combinations, on blood pressure in patients with hypertension. Arch Fam Med. 1996; 5(1): 17–24p. doi:10.1001/ARCHFAMI.5.1.17.
  24. Ambrosioni E, Borghi C, Costa F. Captopril and hydrochlorothiazide: rationale for their combination. Br J Clin Pharmacol. 1987; 23(Suppl 1 ): 43S–50S. doi:10.1111/J.1365 - 2125.1987.TB03121.X.
  25. Frishman WH, Ram CV, McMahon FG, Chrysan t SG, Graff A, Kupiec JW, Hsu H. Comparison of amlodipine and benazepril monotherapy to amlodipine plus benazepril in patients with systemic hypertension: a randomized, double-blind, placebo-controlled, parallel-group study. The Benazepril/Amlodipine Study Group . J Clin Pharmacol. 1995; 35(11): 1060–1066p. doi:10.1002/J.1552-4604.1995.TB04027.X.
  26. Gradman AH, Cutler NR, Davis PJ, Robbins JA, Weiss RJ, Wood BC. Combined enalapril and felodipine extended release (ER) for systemic hypertension. Enalapril -Felodipine ER Factorial Study Group. Am J Cardiol. 1997; 79(4): 431–435p. doi:10.1016/S0002-9149(96)00781-3.
  27. Dahlöf B, Innocenti AD, Elmfeldt D, Puig JG, Gundersen T, Hosie J, Januszewicz W, Lindstorm CJ, Magometschnigg D, Tanser P, Toutouzas P, Waeber B, Wiklund I. Felodipine-metoprolol combination tablet: maintained health -related quality of life in the presence of substantial blood pressure reduction . Am J Hypertens. 2005; 18(10): 1313–1319p. doi:10.1016/J.AMJHYPER.2005.04.017.
  28. Frishman WH, Hainer JW, Sugg J. A factorial study of combination hypertension treatment with metoprolol succinate extended release and felodipine extended release results of the Metoprolol Succinate-Felodipine Antihypertension Combination Trial (M -FACT). Am J Hypertens. 2006; 19(4): 388–395p. doi:10.1016/J.AMJHYPER.2005.10.007.
  29. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial . Lancet (London, England). 2007; 370(9583): 221–229p. doi:10.1016/S0140-6736(07)61124-6.
Support